Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2010
Versatis promotional-code breach
The UK's Prescription Medicines Code of Practice Authority found that material associated with Grünenthal's field teams promoted off-label use of Versatis and contained a misleading cost comparison. The company accepted an undertaking in the case.
2010
Allegation concerning tapentadol promotion
The UK medicines regulator received an allegation that Grünenthal promoted an unlicensed tapentadol product to health professionals. Grünenthal investigated and concluded that the allegation was unsubstantiated.
1957
Thalidomide and the Contergan disaster
Grünenthal marketed thalidomide as Contergan after inadequate assessment of its effects during pregnancy. Exposure caused fetal deaths, miscarriages and severe congenital disabilities in many countries. The medicine was withdrawn in 1961, followed by criminal proceedings, compensation arrangements, regulatory reform and decades of criticism concerning the company's response to victims.